MNTA: I understand there is a threat of TevA approval and the uncertainty of Copaxone and lawsuit. But I think the smaller bulls and even bears did not believe when MNTA got the only approval that it would be trading at a price lower than pre-approval days. The market is looking at MNTA with the glass half empty instead of 3/4's full. So far MNTA has the best situation it could have hoped for- only approval, FDA sets high bar. There may always be that TEVA overhang for the foreseeable future but everyday MNTA rings the cash register. Build up enough sales and people will come around. Maybe in this overall cloudy market climate the glasses are a little foggy. But as many people on this board have reiterated the investment thesis hasn't changed. One layer of risk is gone and we have a reasonable share price again. This small timer may have to change his clothes!
Market Data 
Markets 
AI
